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What does this work add to what is already known? 
Pregnancies complicated by fetal growth restriction present with worse maternal 
hemodynamic function whilst pregnancies with a small for gestational age neonate, 
without evidence of fetal growth restriction, have normal maternal hemodynamic 
function.  
What are the clinical implications of this work? 
Maternal hemodynamic indices may be of value in distinguishing fetal growth 

















Objective: Pregnancies complicated by fetal growth restriction (FGR) have worse 
outcomes than pregnancies with a small for gestational age (SGA) fetus. There is 
increasing evidence of a maternal cardiovascular role in the pathophysiology. We 
aimed to compare the maternal hemodynamic indices (cardiac output and systemic 
vascular resistance) in pregnancies complicated by FGR and pregnancies with an 
SGA fetus using a non-invasive device (USCOM-1A®). 
Methods: This was a prospective study of normotensive pregnancies complicated 
by FGR (defined as pregnancies with a birthweight <3rd centile or with Doppler 
evidence of impaired placental-fetal blood flow), pregnancies with an SGA fetus 
(defined as pregnancies with a birthweight <10th centile) and control pregnancies 
(defined as having an appropriately-grown fetus). Assessment of the maternal 
hemodynamics was performed using a non-invasive device (USCOM-1A®). 
Hemodynamic variables that are affected by gestational age and maternal 
characteristics were corrected for using device-specific reference ranges. Statistical 
analysis was performed using the Chi-square test and the Mann-Whitney test. 
Results: A total of 102 FGR, 64 SGA and 401 control pregnancies at 28-41 weeks’ 
gestation were included in the analysis. Women with pregnancies complicated by 
FGR and pregnancies with an SGA fetus were shorter and weighed less than 
controls. The FGR group had significantly lower median heart rate (80bpm vs 
85bpm, p=0.001), lower cardiac output (0.91MoM vs 0.98MoM, p=0.003), higher 
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mean arterial pressure (90mmHg vs 87 mmHg, p= 0.040), higher systemic vascular 
resistance (1.2MoM vs 1.0MoM, p<0.001) and higher uterine artery pulsatility index 
(1.1MoM vs 0.96MoM, p<0.001) compared to controls, but there was no significant 
difference in stroke volume (p=0.647). The FGR group had a significantly lower 
median heart rate (80bpm vs 87bpm, p=0.022), higher mean arterial pressure 
(90mmHg vs 85 mmHg, p=0.025), higher systemic vascular resistance (1.2MoM vs 
1.0MoM, p=0.002) and higher uterine artery pulsatility index (1.1MoM vs 0.98MoM, 
p=0.005) compared to the SGA group, but there was no significant difference in 
cardiac output (0.91MoM vs 0,96MoM, p=0.092) or stroke volume (1.0MoM vs 
1.0MoM, p=0.806). There were no significant differences in maternal hemodynamic 
indices between the SGA and control groups. 
Conclusion: Pregnancies complicated by FGR present with worse maternal 
hemodynamic function, as evidenced by lower heart rate and cardiac output as well 
as higher mean arterial pressure, systemic vascular resistance and uterine artery 
resistance. Pregnancies resulting in a SGA neonate, without evidence of FGR have 
normal maternal hemodynamic function. Maternal hemodynamic indices may be of 



















Small for gestational age (SGA) pregnancies, and in particular those with fetal 
growth restriction (FGR), are associated with an increased risk of adverse fetal, 
neonatal and longer term childhood outcomes.1–11 Fetal growth restriction is defined 
as a fetus with an estimated fetal weight less than the <3rd centile or a pregnancy 
with impaired placental-fetal blood flow, defined as a uterine or umbilical artery 
pulsatility index >95th centile or absent end-diastolic flow in the umbilical artery (<32 
weeks gestation) or redistribution of cerebral blood flow, defined as a cerebral-
placental ratio <5th centile (≥32 weeks gestation).10,12 Conversely, many SGA 
neonates without these Doppler changes can be considered constitutionally small 
but healthy and likely to have reached their full growth potential. They are at a lower 
risk of adverse outcomes.13 The cause of FGR is not fully understood but incomplete 
physiological transformation of the spiral arteries and the presence of placental bed 
vascular lesions, including thrombosis, infarction, villitis and atherosis, have been 
implicated.14–22 Uterine artery pulsatility index is independently associated with 
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adverse perinatal outcome, regardless of fetal size or fetal umbilical and middle 
cerebral artery Doppler abnormalities.23 Darcy’s Law describes the relationship 
between pressure, flow and resistance; when uterine artery resistance is increased, 
flow will be decreased, resulting in reduced blood flow to the placenta. This reduction 
in flow (and perfusion) may result in FGR. We, and others, have demonstrated that 
uterine artery pulsatility index correlates positively with maternal systemic vascular 
resistance (SVR) and negatively with maternal cardiac output (CO).24,25 This 
suggests that localised resistance at the placenta (and subsequent FGR) may be 
related to underlying differences in maternal hemodynamic function. Previous 
studies have described lower CO and higher SVR in pregnancies affected by both 
SGA and FGR, using both echocardiography and non-invasive cardiac output 
monitors.26–31 However, inconsistencies in the methodology and definitions used, as 
well as the inclusion of patients with hypertension, have made the results harder to 
interpret.  
 
The aim of this study was to investigate maternal hemodynamic indices (CO, stroke 
volume (SV) and SVR) in normotensive pregnancies complicated by FGR or SGA 
without evidence of FGR and in a cohort of control pregnancies. 
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MATERIALS AND METHODS 
 
Study population and recruitment 
This was a prospective case control study including pregnancies with SGA fetuses 
and uncomplicated pregnancies with a normally-grown fetus presenting to a tertiary 
referral hospital between January 2012 and May 2018. The inclusion criteria were 
singleton pregnancies with a viable fetus at 20 weeks’ gestation or greater with SGA 
detected on antenatal ultrasound assessment and a birthweight below the 10th 
centile. The exclusion criteria were multiple pregnancies, pregnancies complicated 
by aneuploidy, genetic syndromes or major structural fetal abnormalities and women 
with a history of chronic hypertension, gestational hypertension or preeclampsia. The 
following definitions were used, as per the ISSHP 2014 criteria:32 
• Chronic Hypertension: ‘hypertension (≥140/90mmHg) that predates 
pregnancy or is present prior to 20 weeks’ gestation.’ 
• Gestational Hypertension: ‘de novo hypertension (≥140/90 mmHg) after 20 
weeks’ gestation.’ 
• Preeclampsia: ‘‘de novo hypertension (≥140/90 mmHg) after 20 weeks’ 
gestation with the coexistence of proteinuria, other maternal organ 
dysfunction or fetal growth restriction.’ 
Those SGA pregnancies that subsequently developed hypertension or resulted in 
the birth of an appropriate for gestational age neonate were excluded from the 
analysis. The SGA group were divided into those with and those without evidence of 
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FGR. Small for gestational age was defined antenatally as an estimated fetal weight 
below the 10th centile and at birth as a neonate with a birthweight below the 10th 
centile. We used a centile calculator derived from a study of 92,000 healthy 
neonates from a similar population to ours.33 Fetal growth restriction was defined as 
per the Delphi Consensus agreement:12 
• <32 weeks: abdominal circumference/estimated fetal weight <3rd centile or 
absent end-diastolic flow in the umbilical artery or abdominal 
circumference/estimated fetal weight <10th centile combined with uterine 
artery pulsatility index >95th centile and/or umbilical artery pulsatility index 
>95th centile. 
• ≥32 weeks: abdominal circumference/estimated fetal weight <3rd centile or at 
least two out of the following: 1. abdominal circumference/estimated fetal 
weight <10th centile, 2. abdominal circumference/estimated fetal weight 
crossing >two quartiles, 3. Cerebral placental ratio <5th centile or umbilical 
artery pulsatility index >95th centile. 
 
The control group consisted of women with no evidence of an SGA fetus antenatally 
and who gave birth to an appropriately-grown neonate. They had no pre-existing 
cardiac or metabolic disease and were recruited whilst attending an antenatal visit or 
an ultrasound assessment (placental localisation, presentation, measuring small or 
large for dates). Written consent was obtained from all study participants and 
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research ethics committee approval (12/LO/0810) was obtained prior to performing 
the study investigations. 
 
Research investigations 
Patients underwent a single hemodynamic investigation at the time of first diagnosis 
of SGA during the pregnancy. Control participants were recruited at any timepoint 
beyond 20 weeks of gestation in the pregnancy. Ultrasound assessment was 
performed on the same day. All hemodynamic assessments were performed in the 
same room, under standardised conditions for the entire cohort. Maternal height, 
weight and brachial blood pressure were obtained prior to hemodynamic 
assessment. Blood pressure was obtained using an upper arm automatic blood 
pressure monitor (Microlife®, Microlife AG Swiss Corporation, Switzerland), in a 
semi-recumbent position and using an appropriately sized cuff. Mean arterial 
pressure (MAP) was calculated as 2 x diastolic blood pressure + systolic blood 
pressure /3. Maternal hemodynamics were assessed using the USCOM 1A® non-
invasive device (Figure 1), while the uterine artery mean pulsatility index was 
recorded using trans-abdominal ultrasound. USCOM 1A® utilises continuous-wave 
Doppler, with a non-imaging probe in the suprasternal notch to obtain velocity time 
integrals of transaortic blood flow at the left ventricular outflow tract. Using an 
internal anthropometric algorithm, which correlates the outflow tract diameter with 
the patient’s height, USCOM 1A® multiplies the velocity time integral by the aortic 
root diameter to calculate SV. By measuring the time interval between each Doppler 
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profile, the heart rate (HR) can be calculated. Cardiac Output (CO = SV x HR) and 
SVR (SVR = MAP/CO)  were calculated after inclusion of the maternal MAP.  
 
Participants remained in a semi-recumbent position and a small amount of 
conducting gel was applied to their skin at the level of the suprasternal notch. The 
Doppler probe was applied and moved through three-dimensions to ensure that the 
velocity of blood was being measured at the left ventricular outflow tract and not in 
the more distal aorta. Each Doppler acquisition used for analysis had a minimum of 
two consecutive Doppler profiles (cardiac cycles) and these were assessed for 
quality by the study investigators. All hemodynamic measurements were performed 
by trained operators. USCOM 1A® has been in clinical use since 2001. The 
repeatability and reproducibility have been assessed in adult, paediatric and 
pregnant populations, demonstrating excellent agreement  between operators with 
sufficient training.34–36 USCOM 1A® has been validated against pulmonary artery 
catheterisation for measurement of cardiac output in adult populations demonstrating 
good agreement,37,38 however it has not been validated against invasive methods 
during pregnancy. Comparison to echocardiography demonstrated good agreement 
in the third trimester however it is clear that measurements from different devices are 
not interchangeable.36 Our group has therefore previously published device-specific 
(USCOM 1A®) reference ranges of the maternal hemodynamic indices in pregnancy, 
using a cohort of 600 uncomplicated pregnancies.39 Once measured,  CO (L/min), 
SV (ml) and SVR (dynes-sec-cm5) measurements were converted into multiples of 
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the median (MoM) based on the expected values of this reference range. This 
calculation adjusted for gestational age as well as maternal height, maternal weight, 
maternal age and maternal smoking status because these characteristics were found 
to have significant correlation with maternal hemodynamic indices.39 
Ultrasound examination was performed by experienced practitioners. Fetal biometry 
and Doppler measurements were undertaken and estimated fetal weight was 
calculated by the Hadlock formula.40 Uterine artery pulsatility index was recorded 
using a standardised technique; the left and right uterine arteries were identified at 
the level of the cross-over of the external iliac artery using colour Doppler. Pulsed-
wave Doppler was used to measure pulsatility index over three consecutive 
waveforms. The mean of the left and right pulsatility index was calculated and 
subsequently converted into MoM to adjust for gestational age in weeks.41 
 
Outcomes 
The primary outcomes were maternal hemodynamic indices [HR (bpm), MAP 
(mmHg), SV (mls), CO (L/min), SVR (dynes-sec-cm5) and uterine artery pulsatility 
index]. Data on the characteristics of participants, gestational age at delivery and 
birthweight were also collected. 
 
Statistical Analysis 
The sample size estimation was based on echocardiographic measurements of 
cardiac output in women with pregnancies complicated by fetal growth restriction and 
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those resulting in small for gestational age fetuses, which demonstrated a difference 
of 1.4L/min (Fetal growth restriction group = 4.7L/min (4.4-5.1), Small for gestational 
age group = 6.1L/min (5.6-6.7).27 The standard deviation was calculated from the 
confidence intervals and a formula for difference in means was used to acquire the 
sample size. We calculated that the enrolment of 62 patients into each group would 
show a difference of half a standard deviation at 80% power and at a significance 
level of 0.05. Data distribution was assessed using the Shapiro-Wilk test as well as 
graphical methods. Categorical data were presented as number and percentage, 
while continuous data were presented as the median and interquartile range (IQR). 
Statistical analysis was performed using the Chi-square and Mann-Whitney tests. 
Spearman’s rank correlation was used to explore the relationship between 
hemodynamic indices and birthweight. A p value <0.05 was considered statistically 
significant. Statistical software (SPSS 25.0; SPSS Inc., Chicago, IL) was used to 
conduct the analysis. 
 





Demographic and Pregnancy Characteristics 
We recruited 208 women with suspected SGA fetuses to this study. Thirty-two were 
excluded from the analysis (31 had a birthweight above the 10th centile and 11 
developed preeclampsia) leaving 102 with a final diagnosis of FGR and 64 with a 
diagnosis of SGA. The control group included 401 women. The demographic and 
pregnancy details are displayed in Table 1. Women with FGR were significantly 
shorter (161cm vs 165cm, p<0.001) and lighter (71.9kg vs 75.7kg, p=0.002) than the 
control group. Women with SGA were also significantly shorter (161cm vs 165cm, 
p=0.002) and lighter (69.4kg vs 75.7kg, p=0.001) than the control group. There were 
no significant differences in the maternal height or weight between the FGR and 
SGA groups. The FGR group had a significantly (all p<0.001) lower median 
birthweight centile (2 vs 7) and gave birth at an earlier median gestation (38.3 weeks 
vs 39.9 weeks) than the SGA group. There was a greater proportion of women of 
Asian ethnicity in both the FGR group (38.2%) and the SGA group (31.3%) 
compared to the control group (17.2%) (p<0.001 and p=0.008, respectively).  
 
Hemodynamic and Ultrasound Investigations 
The FGR group had a significantly lower median HR (80bpm vs 85bpm, p=0.001), a 
lower CO (0.91MoM vs 0.98MoM, p=0.003), a higher MAP (90mmHg vs 87 mmHg, 
p=0.040) a higher SVR (1.2MoM vs 1.0MoM, p<0.001) and a higher uterine artery 
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pulsatility index (1.1MoM vs 0.96MoM, p<0.001) compared to the control group 
(Table 2 and Figure 2). There was no significant difference in SV (1.0MoM vs 
0.98MoM, p=0.647) between the FGR and control pregnancy groups. The FGR 
group had a significantly lower median HR (80bpm vs 87bpm, p=0.022), a higher 
MAP (90mmHg vs 85 mmHg, p=0.025), a higher SVR (1.2MoM vs 1.0MoM, 
p=0.002) and a higher uterine artery pulsatility index (1.1MoM vs 0.98MoM, p=0.005) 
compared to the SGA group. There was no significant difference in CO (0.91MoM vs 
0.96MoM, p=0.092) or SV (1.0MoM vs 1.0MoM, p=0.806) between the FGR and 
SGA groups. There were no significant differences in the maternal hemodynamic 
indices between the SGA and control groups (CO = 0.96MoM vs 0.98MoM, p=0.512, 
SVR = 1.0MoM vs 1.0MoM, p= 0.814).  
 
Birthweight centile was positively correlated with CO MoM (Rs=0.159, p=0.041) and 
negatively correlated with SVR MoM (Rs=-0.223, p=0.004) and uterine artery 
pulsatility index (Rs=-0.246, p=0.002). The correlation between birthweight centile 
and HR (Rs=0.144, p=0.065), SV (Rs=0.041, p=0.602) and MAP (Rs=-0.146, 
p=0.063) was not statistically significant. 
 





Summary of the main study findings 
Pregnancies complicated by FGR present with worse maternal hemodynamic 
function, as evidenced by lower HR and CO as well as higher MAP, SVR and uterine 
artery resistance, when compared to pregnancies with an SGA fetus or healthy 
control pregnancies. Stroke volume is similar in the pregnancies complicated by 
FGR to the pregnancies with an SGA fetus or healthy control pregnancies, 
suggesting that the observed difference in maternal CO is a consequence of lower 
maternal HR.  There were no significant differences in the maternal hemodynamic 
indices in the pregnancies with an SGA fetus compared to the healthy control 
pregnancies. 
 
Interpretation of study findings and comparison with the existing literature 
To date, this is one of the largest studies of normotensive pregnancies complicated 
by FGR and pregnancies with an SGA fetus to describe maternal hemodynamic 
function using a non-invasive cardiovascular device. Roberts et al. compared 
maternal hemodynamic function in 14 patients with FGR at presentation, 53 patients 
with SGA only and 19 SGA pregnancies that subsequently developed FGR. They did 
not find any significant differences in maternal HR, SV or CO between the groups. 
Consistent with our findings, they reported significantly higher MAP and SVR in the 
FGR group at presentation. When they compared the pregnancies complicated by 
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FGR (defined as a birthweight <3rd centile) to those with a birthweight >3rd centile, 
they reported significantly lower maternal HR, SV, CO and higher SVR in the FGR 
pregnancies.31 Stott et al. described longitudinal hemodynamic indices in pregnant 
women with, or at high-risk of hypertension and reported significantly lower CO and 
SV with higher SVR in early pregnancy, predating the development of SGA (n=16).30 
They also noted that women in the SGA group had a higher HR in early pregnancy, 
but that this did not increase with advancing gestation, as seen in healthy controls. In 
a small study using echocardiography, Vasapollo et al. described significantly lower 
cardiac output and higher systemic vascular resistance in normotensive pregnancies 
that were subsequently complicated by FGR compared to those complicated by 
SGA. In their study, the lower cardiac output was a result of both a lower heart rate 
and lower stroke volume. They did not include a control group, so it is unclear if the 
SGA cohort had similar hemodynamic measurements to healthy pregnant women, 
as found in our current study.42 Other echocardiographic findings that have been 
described in FGR include impaired myocardial relaxation and diastolic dysfunction.43 
 
Clinical and research implications 
Our findings demonstrate a high resistance maternal circulation in the pregnancies 
complicated by FGR, even in the absence of maternal hypertension. The 
hemodynamic balance between CO and SVR is dependent on Darcy’s Law of flow, 
pressure and resistance and Bernoulli’s theory of the circulation. Flow (CO) is 
dependent on the pressure difference between two points (MAP – central venous 
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pressure) divided by resistance (SVR). Bernoulli added that pressure, gravitational 
and kinetic energy also influence flow.  The resistance of the systemic circulation is 
located mainly in terminal arteries and arterioles where the pressure difference is 
greatest. The addition of the utero-placental vascular bed during pregnancy 
contributes to the systemic resistance. If this occurs where SVR is already higher, 
the effect will be compounded because resistance in series (end-to-end) is 
summative. Furthermore, vessels with resistance regulate local blood flow and if 
resistance is doubled, conductance will be halved, reducing the blood flow. This 
theory of hydraulics equates to the finding of raised uterine artery resistance in FGR 
(likely secondary to reduced placental flow). The fact that SVR is also raised is 
reflective of the entire circulation and helps to explain the association between 
hypertension and FGR. Furthermore, the fact that these differences are evident pre-
conception and in early pregnancy also supports this theory.44–46 Maternal 
cardiovascular dysfunction has also been reported post-natally following pregnancies 
that were complicated by FGR indicating an underlying contribution of the 
cardiovascular system to the development of FGR, rather than a purely placental 
aetiology.47 
 
A lower maternal HR with no difference in SV in those pregnancies complicated by 
FGR suggests that a relative tachycardia may be a physiological response to the 
increasing metabolic demands of pregnancy. An increased heart rate helps to 
maintain CO against SVR thus ensuring adequate placental blood flow. When this 
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fails to happen, FGR occurs. In SGA pregnancies without FGR, there were no 
differences in maternal hemodynamic indices compared to healthy control 
pregnancies, supporting the hypothesis that these may be ‘normal small’ neonates 
that have met their growth potential, hence the absence of fetal redistribution. 
Assessment of both the maternal and fetal circulations could become a better way of 
understanding, monitoring and managing SGA pregnancies. For example, iatrogenic 
prematurity of ‘normal small’ fetuses may be reduced or conversely, earlier 
intervention before maternal of fetal compromise ensues may be possible. The fact 
that differences in maternal hemodynamic indices can be demonstrated using a non-
invasive device, which has reference ranges for pregnancy,39 is likely to be important 
in terms of increasing research and clinical applicability. 
 
Study limitations and strengths 
The main strengths of our study are that it was prospective in nature and involved a 
large cohort compared to similar published studies. Secondly, no participants were 
hypertensive or taking antihypertensive medication at the time of assessment, 
excluding the effect of such medications on the maternal hemodynamic profile and of 
hypertension as a cause for differences in the hemodynamic function. Finally, we 
corrected the maternal hemodynamic indices for both the gestational age and for 
maternal factors using a device-specific reference range. One limitation of our study 
is that it is cross-sectional in nature and we did not observe longitudinal changes in 
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these pregnancies. We also cannot detect from these results if the differences seen 
pre-dated the pregnancy or not. 
 
Conclusion  
Pregnancies complicated by FGR present with a worse maternal hemodynamic 
profile, as evidenced by lower HR and CO as well as higher SVR and uterine artery 
resistance compared to pregnancies with an SGA fetus and to control pregnancies. 
Pregnancies with an SGA fetus, without evidence of FGR have normal 
hemodynamic function. Maternal HR and other hemodynamic indices may be of 
value in distinguishing SGA pregnancies with and without evidence of FGR.  
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Figure 1: The USCOM 1A® Device 
 
Figure 2: Differences in a) cardiac output multiple of median (MoM), b) heart rate 
(bpm) and c) systemic vascular resistance multiple of median (MoM) between the 
fetal growth restriction group, the small for gestational age group and the control 
group. The P-value represents the comparison to the control group.  
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Table 1. Demographic and pregnancy characteristics of the groups with fetal growth restriction, small for gestational age and 
control pregnancies.  
























Maternal age (years) 31 (25-35) 31 (26-35) 32 (28-36) 0.030 0.047 0.964 
Gestation at assessment (weeks) 35.3 (32.0-36.5) 36.0 (32.4-37.0) 36.0 (31.4-36.4) 0.796 0.321 0.314 
Maternal weight (kg) 71.9 (63.0-82.2) 69.4 (62.5-79.4) 75.7 (68.1-74.1) 0.002 0.001 0.900 
Maternal height (cm) 161 (156-165) 161 (156-167) 165 (160-169) <0.001 0.002 0.893 
Smoker in pregnancy* 5 (4.5) 5 (7.6) 22 (5.5) 0.815 0.460 0.443 
Taking Aspirin in pregnancy for 
prevention of preeclampsia† 
6 (5.9) 2 (3.1) 1 (0.2) <0.001 0.008 0.419 
Nulliparous 65 (59.1) 45 (68.2) 207 (51.6) 0.193 0.011 0.198 
Ethnicity 
  Caucasian 
  Afro Caribbean 
  Asian 































Cerebroplacental Ratio MoM 0.86 (0.66-1.0) 0.99 (0.82-1.2) 1.0 (0.87-1.2) <0.001 0.917 <0.001 
Birthweight centile 2 (0.6-3) 7 (5-9) 50 (25-74) <0.001 <0.001 <0.001 
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*Smoking in pregnancy was defined as any active tobacco intake documented at the booking visit in the first trimester. †Aspirin use 
was defined as any dose commenced during the first or second trimester for the prevention of preeclampsia. 
Data presented as median (interquartile range) or number (%). 
Gestation at delivery (weeks) 38.3 (36.9-39.5) 39.9 (38.7-41.0) 40.0 (39.0-40.9) <0.001 0.793 <0.001 
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Table 2. Maternal hemodynamic indices of the groups with fetal growth restriction, 
small for gestational age and control pregnancies.  
Cardiovascular 
Indices 






























81 (73-88) 81 (75-89) 82 (76-
88) 





90 (79-97) 85 (79-89) 87 (81-
92) 
0.040 0.112 0.025 
Heart Rate 
(bpm) 
80 (72-88) 87 (76-92) 85 (76-
95) 


































































<0.001 0.874 0.002 
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<0.001 0.523 0.005 
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Figure 2: Differences in a) cardiac output multiple of median (MoM), b) heart rate (bpm) and c) systemic 
vascular resistance multiple of median (MoM) between the fetal growth restriction group, the small for 
gestational age group and the control group. The P-value represents the comparison to the control group. 
